This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guth, B. D. Articles by Ross, J. Search for Related Content PubMed PubMed Citation Articles by Guth, B. D. Articles by Ross, J., Jr Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Circulation, Vol 75, 661-669, Copyright © 1987 by American Heart Association

ARTICLES

Elimination of exercise-induced regional myocardial dysfunction by a bradycardiac agent in dogs with chronic coronary stenosis

BD Guth, G Heusch, R Seitelberger and J Ross Jr

We have previously demonstrated that the beneficial effect of cardioselective beta-blockade on exercise-induced ischemia is due entirely to negative chronotropism. Therefore we studied the effect of a new bradycardiac agent (UL-FS 49) in 10 dogs with chronic coronary artery stenosis produced by an ameroid constrictor. Regional myocardial function (sonomicrometers, wall thickness) and blood flow (microspheres) were measured during a control treadmill exercise bout and an identical run 3 hr later after the administration of UL-FS 49 (1.0 mg/kg iv). In the control run, heart rate increased from 114 +/- 20 to 230 +/- 19 beats/min and systolic wall thickening (%WT) in the poststenotic myocardium decreased from 23.3 +/- 5.2% at rest to 9.3 +/- 5.0%, a 60% reduction. Subendocardial blood flow in the ischemic area decreased from 1.04 +/- 0.30 to 0.55 +/- 0.40 ml/min/g, blood flow per beat decreased from 9.1 X 10(-3) to 2.5 X 10(-3) ml/g, and mean transmural flow failed to increase (1.06 +/- 0.30 vs 1.08 +/- 0.39 ml/min/g). During exercise with UL-FS 49, heart rate increased from 89 +/- 10 to only 139 +/- 10 beats/min. End-diastolic left ventricular pressure was increased compared with that during the control run (35.7 +/- 3.0 vs 28.9 +/- 5.5 mm Hg) but left ventricular peak systolic pressure and dP/dt were unchanged. %WT in the ischemic zone did not change significantly during exercise with UL-FS 49 (23.3 +/- 7.9% at rest, 21.5 +/- 8.4% during the run), and in the nonischemic zone it increased to the same extent as during the control run.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				G. Heusch A BEAUTIFUL lesson--ivabradine protects from ischaemia, but not from heart failure: through heart rate reduction or more? Eur. Heart J., October 1, 2009; 30(19): 2300 - 2301. [Full Text] [PDF]

				G. Heusch, A. Skyschally, P. Gres, P. van Caster, D. Schilawa, and R. Schulz Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction Eur. Heart J., September 2, 2008; 29(18): 2265 - 2275. [Abstract] [Full Text] [PDF]

				G. Heusch and R. Schulz The role of heart rate and the benefits of heart rate reduction in acute myocardial ischaemia Eur. Heart J. Suppl., September 1, 2007; 9(suppl_F): F8 - F14. [Abstract] [Full Text] [PDF]

				P. Mulder, S. Barbier, A. Chagraoui, V. Richard, J. P. Henry, F. Lallemand, S. Renet, G. Lerebours, F. Mahlberg-Gaudin, and C. Thuillez Long-Term Heart Rate Reduction Induced by the Selective If Current Inhibitor Ivabradine Improves Left Ventricular Function and Intrinsic Myocardial Structure in Congestive Heart Failure Circulation, April 6, 2004; 109(13): 1674 - 1679. [Abstract] [Full Text] [PDF]

				X. Monnet, P. Colin, B. Ghaleh, L. Hittinger, J.-F. Giudicelli, and A. Berdeaux Heart rate reduction during exercise-induced myocardial ischaemia and stunning Eur. Heart J., April 1, 2004; 25(7): 579 - 586. [Abstract] [Full Text] [PDF]

				K. Hu, A. Naumann, D. Fraccarollo, P. Gaudron, J. J. Kaden, S. Neubauer, and G. Ertl Heart rate reduction by zatebradine reduces infarct size and mortality but promotes remodeling in rats with experimental myocardial infarction Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1281 - H1288. [Abstract] [Full Text] [PDF]

				J.P. Vilaine, C. Thollon, N. Villenueve, and J.L. Peglion Procoralan, a new selective If current inhibitor Eur. Heart J. Suppl., September 1, 2003; 5(suppl_G): G26 - G35. [Abstract] [PDF]

				X. Monnet, B. Ghaleh, P. Colin, O. P. de Curzon, J.-F. Giudicelli, and A. Berdeaux Effects of Heart Rate Reduction with Ivabradine on Exercise-Induced Myocardial Ischemia and Stunning J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1133 - 1139. [Abstract] [Full Text] [PDF]

				C. Kruger, V. Landerer, C. Zugck, H. Ehmke, W. Kubler, and M. Haass The bradycardic agent zatebradine enhances baroreflex sensitivity and heart rate variability in rats early after myocardial infarction Cardiovasc Res, March 1, 2000; 45(4): 900 - 912. [Abstract] [Full Text] [PDF]

				T Laperche, D Logeart, A Cohen-Solal, and R Gourgon Potential interests of heart rate lowering drugs Heart, April 1, 1999; 81(4): 336 - 341. [Full Text]

				T. Neumann, U. Ravens, and G. Heusch Characterization of excitation-contraction coupling in conscious dogs with pacing-induced heart failure Cardiovasc Res, February 1, 1998; 37(2): 456 - 466. [Abstract] [Full Text] [PDF]

				C. Valenzuela, E. Delpon, L. Franqueza, P. Gay, O. Perez, J. Tamargo, and D. J. Snyders Class III Antiarrhythmic Effects of Zatebradine: Time-, State-, Use-, and Voltage-Dependent Block of hKv1.5 Channels Circulation, August 1, 1996; 94(3): 562 - 570. [Abstract] [Full Text]

				J. Ross Jr, T. Miura, M. Kambayashi, G. P. Eising, and K.-H. Ryu Adrenergic Control of the Force-Frequency Relation Circulation, October 15, 1995; 92(8): 2327 - 2332. [Abstract] [Full Text]